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Background
OnabotulinumtoxinA (Botox®, Allergan) has shown its
efficacy in chronic migraine (CM) in two phase III stu-
dies and up to 5 injection cycles [1]. However, few stu-
dies have been published based on its real life efficacy
and few data are available on its efficacy beyond the 5th
cycle of treatment [2].
Objective
To assess the real life efficacy of 155U-195U Onabotuli-
numtoxinA in CM patients in order to retrospectively
investigate the benefits of such treatment and observe if
the efficacy is sustained after one year.
Methods
We reviewed the charts of 134 patients treated with Ona-
botulinumtoxinA who received up to 9 cycles. Patients
were injected regularly with a 3-month (±10 days) interval.
They were assessed for headache days and hours, intensity
of pain by Visual Analogue Scale (VAS), number of any
acute drug intake. Photophobia, phonophobia, osmopho-
bia, nausea were assessed as well. The results were also
analysed based on the CM onset.
Results
Since approval, we have treated a total of 134 patients. We
collected the data of 113 CM patients (mean age 48 y.o.;
76% women) who represent the ones showing any
response during the first two treatment cycles. Already
after cycle two, those who were responders, showed a high
decrease vs the baseline as follows: 54% in headache days
reduction (from 24.1 to 11.1); 64% in headache hours
(from 552.8 to 199). Also, pain intensity dramatically
decreased 21% (from 9.6 to 7.6) and correspondingly any
drug intake went from an average of 51.65 to 16 tablets/
month. In the case of those patients also taking i.v. drugs,
these had been totally suspended from the second cycle
since there was no need. Thirty-seven patients had been
treated longer than one year and up to 9 cycles confirming
an increasing improvement over time (Table 1). No differ-
ence in efficacy was recorded comparing patients suffering
from CM from 5 up to 20 years.
Conclusions
Our real life experience demonstrated the efficacy and tol-
erability of the OnabotulinumtoxinA responders already
after the first treatment cycles. Overtime, not only a sus-
tained efficacy was observed but also a favorable trend of
improvement with no significant adverse events. Moreover,
our analysis confirmed that the efficacy outcomes were not
affected by the CM onset thus allowing us to assume that
OnabotulinumtoxinA can be considered a valuable first
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Table 1
Time in months Headache Days % of Reduction vs Baseline
Baseline 24.1 (22.1 - 26.3)
3 16.4 (14.8 - 18.1) 32
6 11.1 (9.7 - 12.7) 54
9 7.5 (6.3 - 9.1) 69
12 5.1 (4.0 - 6.5) 79
15 3.5 (2.6 - 4.7) 85.5
18 2.4 (1.7 - 3.3) 90
21 1.6 (1.1 - 2.4) 94.4
24 1.1 (0.7 - 1.7) 95.4
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line treatment to allow more patients to benefit earlier and
more consistently from this therapeutic option.
Written informed consent to publish was obtained
from the patient(s).
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